Daily Archives: November 7, 2017

The Future is Now: International Association of Business Analysis (IIBA) puts the spotlight on business transformation at 2017 Building Business Capability (BBC) Conference

From November 6-10, 2017, IIBA members will convene in Orlando, Florida for keynote speeches, tutorials, networking opportunities and a vendor exhibition

Oakville, ON, Nov. 07, 2017 (GLOBE NEWSWIRE) — From November 6 to 10, 2017, International Institute of Business Analysis™ (IIBA®) members from around the world will convene at the Loews Royal Pacific Resort in Orlando, Florida for the annual Building Business Capability (BBC) Conference to explore the evolution of the industry. Considered the world’s largest global gathering of business analysis (BA) professionals, this year’s conference offers a series of spotlight sessions focused on next generation business analysis led by industry veterans who will share their perspectives on how BAs can prepare their organizations to successfully address impending change and stay relevant. Attendees will also have access to tutorials, networking sessions, and a vendor exhibition.  

“We’re witnessing a digital transformation that is indeed evolving the traditional business analysis role. While fundamental skills are still important to possess, as dedicated BA professionals, we’re constantly being challenged to re-skill with higher level capabilities – that’s just the new business reality,” says Ken Fulmer, CEO, IIBA. “I look forward to welcoming my peers to BBC and hearing from our esteemed speakers on this subject.”

BAs operate under a variety of titles and are involved in many facets of an organization. However, they all work within the same strategic framework of Business Analysis.

Those attending the conference, and others who want to join in on the conversation, can do so by using the hashtag #BBCCon.

About International Institute of Business Analysis™ (IIBA®)

International Institute of Business Analysis™ (IIBA®) is a professional association dedicated to helping the business analysis community create better business outcomes. Through a global network, IIBA connects more than 29,000 Members and more than 300 Corporate Members and 120 Chapters. As the voice of the business analysis community, IIBA supports the recognition of the profession and discipline and works to maintain the global standard for the practice and certification.

Learn more about IIBA through the organization’s Facebook, LinkedIn and Twitter page

Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/914d873b-25f0-421d-812f-105d3dbfad13

Ann Cain
International Institute of Business Analysis 
647-346-0372
ann.cain@iiba.org

Jessica Squibb
Ketchum
416-355-7412
jessica.squibb@ketchum.com

Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Software

SAN DIEGO, Nov. 07, 2017 (GLOBE NEWSWIRE) — Invivoscribe® Technologies Inc., a global company with decades of experience providing clonality and biomarker test solutions for the fields of oncology and personalized molecular medicine®, announces the release of the Research Use Only (RUO) version of its LymphoTrack® TRB Assay for the Illumina MiSeq® platform. Included with the assay is specialized bioinformatics software that allows researchers and pharmaceutical companies conducting clinical trials, to identify and track clonal populations by performing minimal residual disease (MRD) testing of subsequent samples.

Tests that detect TRB clonal rearrangements are useful in the study of T-cell malignancies as leukemias and lymphomas generally share one or more cell-specific or “clonal” antigen receptor gene rearrangement(s). The LymphoTrack® TRB Assay on MiSeq® identifies clonal TRB (VDJ) rearrangements, the associated VDJ region DNA sequences, and provides the frequency distribution of V, D, and J, region segment utilization using the included LymphoTrack® bioinformatics software. This assay will increase the probability of identifying T cell receptor beta chain gene rearrangements versus when testing for TRG gene rearrangements only.

The LymphoTrack® TRB Assay completes the comprehensive menu of Invivoscribe LymphoTrack® Clonality Assays which enable rapid clonal rearrangement identification with the unparalleled accuracy and sensitivity of next generation sequencing (NGS). The LymphoTrack® product line allows customers to simultaneously run any combination of assays, thus significantly reducing both cost and time to results. The kit includes LymphoTrack® MiSeq® software which automates the sorting and individual tracking of each sample and IGH, IGK, TRG and TRB target, interprets sequence data, and generates succinct, yet comprehensive reports for each sample and each target. The LymphoTrack® MRD software enables temporal tracking of clonal populations, and has demonstrated potential to improve subject monitoring in clinical trial and research settings. Both the LymphoTrack® MiSeq® and MRD software programs facilitate international standardization and objective interpretation for clonality and MRD testing. Invivoscribe will also seek CE IVD marking of a LymphoTrack® TRB Assay for sale of kits to laboratories outside North America, and 510(k) clearance in the United States. We have already started this process for our menu of LymphoTrack® Clonality Assays.

About Invivoscribe

Invivoscribe® Technologies Inc. is a privately held biotechnology company dedicated to improving the quality of healthcare worldwide by providing high quality, reliable, cutting-edge reagents, tests, and bioinformatics tools to advance the fields of personalized molecular diagnostics® and personalized molecular medicine®.  Invivoscribe provides PCR and NGS-based reagents and bioinformatics software designed and manufactured in an ISO 13485 accredited facility registered with the FDA; RUO test kits; CE-marked IVDs, including IdentiClone® and LymphoTrack® Dx Assays with both LymphoTrack® and LymphoTrack® Dx Software; for clonality, MRD, and somatic hypermutation testing. Invivoscribe’s clinical laboratories also offer comprehensive MyAML®, MyHeme®, MyMRD®, and custom gene panels, that when used in combination with Invivoscribe’s proprietary MyInformatics® Software can identify and track primary driver mutations as well as the subclonal architecture and emergence of new driver mutations in patients with hematologic disease. Invivoscribe’s clinical laboratories in the USA, Europe, and Japan provide international access to harmonized CLIA, CAP, and ISO 15189 accredited clinical testing and contract research organization (CRO) services.  Invivoscribe’s tests, reagents and bioinformatics tools are currently being used in more than 700 clinical and research laboratories in more than 102 countries. Invivoscribe also has proven expertise in development and commercialization of companion diagnostics. As a global leader, Invivoscribe has long embraced the value of quality systems and develops all IVD products, including bioinformatics software in compliance with ISO 13485 design controls, making them eligible to be submitted to worldwide regulatory authorities for registration.  For additional information please visit www.invivoscribe.com.

CONTACT:
Kevin Dobyns 858-224-6600

YPO Global Pulse Survey: Business confidence in Asia rebounds in third quarter but outlook slips in Australasia

China reports major increase in confidence as Japan slumps to five-year low

HONG KONG, Nov. 06, 2017 (GLOBE NEWSWIRE) — YPO, the premier leadership organization for chief executives in the world, reported today that confidence among business leaders in Asia crept up in the third quarter of 2017 (3Q 2017).

The YPO Global Pulse Confidence Index for Asia climbed 1.3 points to 62.8, making Asia the third most confident region, after the United States (63.5) and Australasia (63.3), remaining firmly in optimistic territory and suggesting that economic conditions in Asia are stable, although there were strong variances among the major economies in the region.

China reported a big upturn in sentiment, jumping 8.8 points to 68.0, its highest level since April 2013, while Japan dropped 3.9 points to 50.6, its lowest level for five years.

Confidence in India remained steady, edging up 0.5 point to 65.9, lower than that of China for the first time in over a year but still positive. The region’s emerging economies showed a definite improvement, and confidence in the Association of Southeast Asian Nations (ASEAN) jumped 3.0 points to 63.8.

“Once again, chief executives across the region remain positive about growth opportunities for in the short- to medium-term,” said YPO member, and CEO and President of PBM Polytex, Amit Gopal Patodia. “With commodity prices continuing to rise and moderate GDP growth forecast for 2018 and beyond, business leaders will be keen to take advantage of the current economic climate. However, they will undoubtedly be keeping a close eye on the socio-political landscape.”

Key findings in Asia

Economic climate in Asia set to improve

The majority of respondents (53%) predicted that business conditions would improve over the next six months, versus only 10% who believed that the economic environment would deteriorate. Regarding the three key indicators of the survey, namely sales, employment and fixed investment, business leaders continued to be optimistic about the prospects for their own organizations over the next 12 months.

Asia was the most confident region in the world for sales outlook, with 63% of respondents expecting to increase revenue over the coming year, and only 5% predicting a decline in turnover.

Employment confidence jumped 3.6 points to 58.9, its highest level since July 2014, with 57% of respondents expecting their workforce to remain the same, over a third (38%) expecting to increase headcount, while 5% predicted cuts. This was an improvement from 2Q 2017, when only 28% predicted a greater headcount 12-months hence.

For fixed investment, confidence climbed 3.6 points to 62.9, reversing most of the 3.9-point decline in the 2Q. Almost half (48%) of respondents expected to increase fixed investment spending, and only 8% predicted a reduction in investment levels.

Key findings in Australasia

Confidence drops, but chief executives remain bullish

Overall confidence in Australasia fell 3.7 points to second place at 63.3, overtaken by the United States (63.5).

However, Australasians are still extremely positive, and 54% expect conditions to improve over the next six months, compared with only 11% who predicted a decline. The remaining 35% believe that economic conditions will remain the same.

When assessing the prospects for their own organisations over the next year, two-thirds (68%) expected to increase sales, and only 5% predicted a decline in revenue.

When it came to hiring, 43% of respondents expected to increase headcount, and 8% predicted cuts. Finally, half (50%) expect to increase fixed investment spend, and only 6% forecasted a decline in investment levels.

Global review

Globally, confidence remained steady at 62.4, now firmly in positive territory for four consecutive surveys, hovering between of 62.0 and 62.5. The United States was the most confident region at 63.5, Canadian confidence also remained positive, declining marginally by 1.1 points to 61.8. In Europe, the mood remained upbeat, as the European Union (EU) slipped slightly by 1.2 points to 61.8, and non-EU Europe edged down 1.7 points to 58.6.

Elsewhere, confidence in Latin America jumped 2.8 points to 62.0, largely driven by Brazil’s 8-point hike in confidence. In Africa, confidence edged up 1.2 points to 57.5, yet it remains the second least-confident region, trailed only by the Middle East and North Africa (MENA) region, where confidence increased 2.5 points to 53.2.

YPO Global Pulse Confidence Index
The quarterly electronic survey, conducted in the first two weeks of October 2017, gathered answers from 925 YPO chief executive officers across the globe, including 103 in Asia and 40 in Australasia. Visit http://www.ypo.org/globalpulse/ for more information about the survey methodology and results from around the world.

About YPO

The premier leadership organization of chief executives in the world.

YPO is the global platform for chief executives to engage, learn and grow. YPO members harness the knowledge, influence and trust of the world’s most influential and innovative business leaders to inspire business, personal, family and community impact.

Today, YPO empowers more than 25,000 members in more than 130 countries, diversified among industries and types of businesses. Altogether, YPO member-run companies employ more than 16 million people and generate USD6 trillion in annual revenues.

Leadership. Learning. Lifelong. For more information, visit‪ YPO.org.

Contact:
YPO
Linda Fisk
Office: +1 972 629 7305 (United States)
Mobile: +1 972 207 4298
press@ypo.org ,